Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

Authors

null

Stephanie L. Wethington

Johns Hopkins University, Baltimore, MD

Stephanie L. Wethington , Payal D Shah , Lainie P. Martin , Janos Laszlo Tanyi , Nawar A. Latif , Mark Aloysuis Morgan , Drew A. Torigian , Cheyenne Pagan , Diego Rodriguez , Susan M. Domchek , Ronny Drapkin , Ie-Ming Shih , Simon Smith , Emma Dean , Deborah Kay Armstrong , Stephanie Gaillard , Fiona Simpkins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03462342

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5516)

DOI

10.1200/JCO.2021.39.15_suppl.5516

Abstract #

5516

Abstract Disclosures